Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | AKT1 | P31749 | 3/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4187556 | 0.85 | CA12 (0.43) | CA12CA1CA7CA14SYK | |
| SCHEMBL8011499 | 0.81 | CA12 (0.52) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL31407962 | 0.77 | CA12 (0.48) | CA12CA1CA7CA14SYK | |
| SCHEMBL25347291 | 0.75 | CA12 (0.46) | CA12CA1CA7CA14SYK | |
| SCHEMBL4187558 | 0.75 | CA12 (0.48) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL6494733 | 0.74 | CA1 (0.67) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL28827505 | 0.73 | CA12 (0.45) | CA12CA1CA7CA14CA2 | |
| SCHEMBL421286 | 0.72 | SYK (0.61) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL13940771 | 0.71 | CA12 (0.59) | CA12CA1CA7CA14AKT1 | |
| SCHEMBL14979842 | 0.71 | CA1 (0.52) | CA12CA1CA7CA14SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8093379-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2250174-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CA12 3795/4885CA1 3949/4885CA7 4452/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CA12 3795/4885CA1 3949/4885CA7 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.